Although I am in agreement, I see things a little...

Although I am in agreement, I see things a little differently.

Ultimately, as long as trials are designed correctly, bisantrene and all it's benefits are predetermined. We just have to prove or be proven wrong. Whether we take a smaller or larger buyout, early or late, I don't feel it will speed the process to approval. Ultimately, big pharma's will be looking to maximise revenue whether the buyout is large or small.

So, my opinion is that all we are doing with a smaller buyout is helping the big pharma collect a larger profit margin. Big Pharma's just like any large conglomerate is beholden to shareholders. And most shareholder's are interested in one thing.

This is my own attempt at logical thinking, so I would be happy to be proven wrong by those more intimate in the process.